Vesalius Biocapital holds €65m first close for third fund

Vesalius Biocapital III is aiming for a final close on €150m in 2018, and until that point will accept new investors on a "rolling closing" basis, the VC said in a statement. It will have a particular focus on existing portfolio companies within five years.

In parallel with the first close, Vesalius is establishing a Boston-based presence to facilitate access to US capital markets for European companies and for North American companies to have access to Europe for development, expansion or access to innovation.

Vesalius has raised in excess of €150m since inception 10 years ago. Vesalius Biocapital I closed on €76m, having launched in 2007, and is fully invested in 11 portfolio companies. Vesalius Biocapital II was launched in 2011 and raised €78m; like its predecessor, it is also fully invested in 11 portfolio companies.

Investments
The fund will now start to invest in later-stage European life sciences companies across drug development, medical technology, diagnostics and digital health, providing capital to support their development.

People
Vesalius Biocapital – Guy Geldhof, Marc Lohrmann, Christian Schneider, Stéphane Verdood (managing partners); Cees Wortel, David Braga Malta (venture partners).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Benelux
• Healthcare
• Venture
• Luxembourg